Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Closes US IPO, Raising $84.8M

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

The Israel-based plant genomics firm went public in the US last week. It said today that underwriters on the offering exercised their option in full to purchase up to 750,000 additional shares at $14.75 per share, the same price as in its public offering. Credit Suisse Securities and Deutsche Bank Securities were joint book-running managers, while Oppenheimer and Piper Jaffray were co-managers on the offering.

The company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.